Effect of inhaled beta2 agonist on lung compliance in patients with COPD with poor bronchodilator response Source: Eur Respir J 2006; 28: Suppl. 50, 428s Year: 2006
Increased airway responsiveness to beta-adrenergic agonists in asthmatic patients Source: Eur Respir J 2005; 26: Suppl. 49, 582s Year: 2005
The effect of leukotrienes receptor antagonists on lung function, exercise tolerance and incidence of exacerbations in patients with stable, moderate COPD Source: Eur Respir J 2002; 20: Suppl. 38, 620s Year: 2002
An oral selective M3 cholinergic receptor antagonist in COPD Source: Eur Respir J 2006 Oct 01;28(4):772-780 Year: 2006
Airway resistance assessed by impulse oscillometry at varying respiratory rate and the effect of pretreatment with short-acting β2 agonist in COPD patients Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
EP2 & EP4 receptor agonists inhibit the airway sensory nerves that cause cough, a potential protective control that is lost in human smokers and a pre-clinical COPD model Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017
Paradoxical bronchoconstriction after administration of beta-2 agonist bronchodilators in COPD patients Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020
Effect of an inhaled adenosine A2A agonist on the allergen induced late asthmatic response Source: Eur Respir J 2003; 22: Suppl. 45, 204s Year: 2003
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Effect of long-acting muscarinic antagonist (LAMA) on 24-hour physical behaviours in COPD Source: Virtual Congress 2020 – Reviews and novel insights into pulmonary rehabilitation Year: 2020
Long acting bronchodilation of Spiriva® handihaler in COPD patients, the influence of the inhalation flow rate (IFR) Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Combination of beta2 agonists and anticholinergic drugs improves lung function in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 726s Year: 2006
Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011
Salmeterol response is not affected by beta2 -adrenergic receptor genotype in patients with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 505s Year: 2005
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
The gln27 beta adrenoceptor polymorphism is associated with bronchodilator reversibility in subjects with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 96s Year: 2002
Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Airway responsiveness to beta-adrenergic agonist in smokers Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004